Goldman Sachs Group Inc Roivant Sciences Ltd. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,937,367 shares of ROIV stock, worth $52.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,937,367
Previous 2,433,386
20.71%
Holding current value
$52.1 Million
Previous $24.6 Million
34.83%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding ROIV
# of Institutions
363Shares Held
456MCall Options Held
8.36MPut Options Held
760K-
Sb Investment Advisers (Uk) LTD London, X060MShares$1.06 Billion5.36% of portfolio
-
Morgan Stanley New York, NY44.7MShares$793 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA39.3MShares$698 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$627 Million0.01% of portfolio
-
Viking Global Investors LP34.2MShares$607 Million1.22% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $12.5B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...